cisplatin

Cisplatin is a "first generation" antitumor drug highly effective in the chemotherapy of many forms of cancer. Thge metallodrug is most commonly used to treat testicular, bladder, lung, gullet (oesophagus), stomach and ovarian cancers. The water-soluble platinum complex, after hydrolysis, reacts with the nucleic acid bases of DNA to produce both intra and interstrand crosslinks. These crosslinks appear to impair replication and transcription of DNA. The cytotoxicity of cisplatin correlates with cellular arrest in the G2 phase of the cell cycle.
 
IUPAC name: cis-diamminedichloroplatinum(II).



The term "cisplatin" was found in the following pages:

Side effects of cisplatin chemotherpy: Platinum speciation matters | EVISA's News
Link database: DrugBank: Cisplatin
Scientific publications with participation of EVISA | EVISA's News
Speciation and Toxicity | EVISA's News
Ultra-sensitive speciation analysis of inorganic platinum-chloride complexes in platinum-based drugs by HPLC-ICP-MS | EVISA's News
Brief summary: Speciation analysis for the study of metallodrugs and their biomolecular interactions | EVISA's News
Link database: Austria: University of Vienna: Institute of Inorganic Chemistry: Working group of B. Keppler
Link database: Chemocare: Cisplatin
Link database: Speciation, bioavailability and antigenotoxicity of Selenium species present in Selenium enriched natural products.
A new quantification strategy for bioimaging by laser ablation - inductively coupled plasma-mass spectrometry based on isotope dilution analysis | EVISA's News
Link database: Cisplatin: Cancerbackup
Spatially resolved speciation analysis: A new technique based on laser ablation with simultaneous elemental and molecular mass spectrometry | EVISA's News
Species transformation during speciation analysis | EVISA's News
„Forever young“ oder wirklich jung? - Metallomics im Fokus der Biochemie | EVISA's News
Link database: Lipoplatin -
ESI-MS: The tool for the identification of chemical species | EVISA's News
Nanoscale Metal-Organic Frameworks (NMOFs): A new way to create better MRI Contrast Agents | EVISA's News
Link database: National Cancer Institute: Cisplatin
Link database: DrugBank: Oxaliplatin
Link database: Cisplatin, Carboplatin, and Oxaliplatin Interactions With Plasma Proteins